GTHX - G1セラピュ―ティクス (G1 Therapeutics Inc.)


   Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More  2019/09/30 13:13:00 Benzinga
The five-day European Society of Medical Oncology, or ESMO, Congress 2019 is set to conclude Tuesday in Barcelona, Spain. Touted as a congress where …
   Harry Boxer’s three biotech stocks on the move include Nektar Therapeutics  2019/06/19 17:58:00 MarketWatch
Also in focus: G1 Therapeutics and Iovance Biotherapeutics.
   G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer  2019/06/18 10:00:00 Yahoo Finance
G1 Therapeutics, Inc. (GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from a randomized Phase 2 trial which demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy
   G1 Therapeutics, Inc. (GTHX) Q1 2019 Earnings Call Transcript -- The Motley Fool  2019/05/13 17:12:29 The Motley Fool
GTHX earnings call for the period ending March 31, 2019.
   G1 Therapeutics to Present at UBS Global Healthcare Conference  2019/05/13 11:00:00 Benzinga
RESEARCH TRIANGLE PARK, N.C., May 13, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ: GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the UBS Global Healthcare Conference. The presentation will take place on Tuesday, May 21 at 4:00 p.m. ET at the Grand Hyatt New York in New York, NY. To access the live webcast presentation, please visit the … Full story available on
   G1 Therapeutics Looks To Regulatory Agency For Its Bone Marrow Preservation Drug  2019-05-07
G1 Therapeutics Inc. ( GTHX ) announced that it had achieved a positive end of phase 2 meeting with the FDA with its drug trilaciclib for myelopreservation in small cell lung cancer ((SCLC)). The biotech also has a few other drugs that it is working on that could potentially be an improvem…